Pfizer (PFE) Offers 6.9% Dividend Yield Amid New Drug Development
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowPfizer (PFE) has been identified as a solid dividend stock, currently offering a forward-looking dividend yield of 6.9%. The company is focused on developing new profit centers, including acquiring Seagen in 2023 to enhance its oncology pipeline. By 2030, Pfizer anticipates launching at least eight new blockbuster drugs, supported by both acquisitions and internal development. This potential for new drugs reinforces Pfizer's ability to continue providing dividends, which is important for investors seeking steady income.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Pfizer Inc. (PFE)
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier PFE news
- Trump's Generic Drug Tariffs to Hit 100% by August 2028
- Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
- Pfizer (PFE) Offers Attractive Dividend Yield for Investors
- PFE and JNJ Annual Dividend Income of $3,540 for Investors
- Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Chinese Equities See Earnings Forecasts Fall Amid Prolonged Downturn
Oct 25
Climb Bio Reports Early Trial Data on Budoprutug for Kidney Diseases
Oct 24
Trade Desk (TTD) CEO Overrides Investor Opposition to Option Repricing
Oct 24
iShares Biotech ETF (IBB) Surges 24% Year-To-Date Amid Moderna's 587% Gain
Oct 24